- Home
- RMCF vs RNTX Comparison
RMCF vs RNTX Comparison
Compare RMCF & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | RNTX |
|---|---|---|
| Founded | 1981 | 2001 |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 30.0M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | RNTX |
|---|---|---|
| Price | $2.22 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 17.8K | ★ 119.9K |
| Earning Date | 01-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $1.02 |
| 52 Week High | $2.99 | $2.22 |
Technical Indicators
Market Signals| Indicator | RMCF | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 66.36 |
| Support Level | $1.47 | $1.34 |
| Resistance Level | $2.59 | $1.59 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 43.06 | 74.58 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.